Bide Pharmatech Valuation
Is 688073 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 688073 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 688073's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 688073's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 688073?
Other financial metrics that can be useful for relative valuation.
What is 688073's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥3.15b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.8x |
Enterprise Value/EBITDA | 20.3x |
PEG Ratio | 0.8x |
Price to Earnings Ratio vs Peers
How does 688073's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 60.1x | ||
301258 Suzhou Fushilai Pharmaceutical | 49.2x | n/a | CN¥3.3b |
002198 Guangdong Jiaying Pharmaceutical | 114.3x | n/a | CN¥3.1b |
301201 ChengDa Pharmaceuticals | 34.8x | n/a | CN¥3.1b |
688117 ChengDu ShengNuo BiotecLtd | 42.1x | 33.9% | CN¥3.1b |
688073 Bide Pharmatech | 31.9x | 42.1% | CN¥3.2b |
Price-To-Earnings vs Peers: 688073 is good value based on its Price-To-Earnings Ratio (31.9x) compared to the peer average (60.1x).
Price to Earnings Ratio vs Industry
How does 688073's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 688073 is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the CN Pharmaceuticals industry average (30.4x).
Price to Earnings Ratio vs Fair Ratio
What is 688073's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 31.9x |
Fair PE Ratio | 35.3x |
Price-To-Earnings vs Fair Ratio: 688073 is good value based on its Price-To-Earnings Ratio (31.9x) compared to the estimated Fair Price-To-Earnings Ratio (35.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.